Image may be NSFW.
Clik here to view.
Clik here to view.
Gamida Cell shifts focus to NiCord stem cell product
Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Leerink starts FATE Therapeutics at outperform
Leerink Partners has initiated coverage of FATE Therapeutics (NASDAQ:FATE) with an “outperform” rating and $10 price target in 12 months. The stock closed at $6.26 on Friday. FATE is focused on...
View Article
More Pages to Explore .....
